Europe EditionDisparities in Access to Novel Infusion Treatment for Alzheimer's Disease Revealed
- A study published on May 12, 2025, in JAMA Neurology reported real-world use of lecanemab at a specialty memory clinic in St. Louis, Missouri.
- The study examined 234 patients with early Alzheimer's disease over a 14-month period following FDA approval in July 2023 of lecanemab, the inaugural therapy aimed at altering the course of the disease.
- Results showed 1%-2% of patients experienced clinically concerning side effects like brain swelling and bleeding, which were manageable and similar to clinical trial findings.
- An analysis of Medicare data from July 2023 to March 2024 found 1,725 lecanemab users were disproportionately male , white , urban , and wealthier compared to 842,192 eligible patients.
- These disparities persist despite manufacturer assistance programs, highlighting access inequities and suggesting a need for policy attention and further real-world data collection.
12 Articles
12 Articles
Large disparities in adoption of Alzheimer's infusion therapy raise concerns about access
Adoption of lecanemab, a novel infusion treatment for Alzheimer's disease (AD), has been disproportionately higher among patients who are male, white, from urban areas, and have higher socioeconomic status, new research suggests.
Disparities in access to novel infusion treatment for Alzheimer's disease revealed
Adoption of lecanemab, a novel infusion treatment for Alzheimer's disease (AD), has been disproportionately higher among patients who are male, white, from urban areas, and have higher socioeconomic status, new research suggests.
MedPage Today
Anti-Aging, Acupuncture and Health NewsAlzheimer's Drug Used Mainly by Relatively Affluent, Urban White Men
(MedPage Today) -- Uptake of lecanemab (Leqembi), a monoclonal antibody approved to treat early Alzheimer's disease, appeared to be marked by racial, ethnic, and socioeconomic disparities, an analysis of Medicare data suggested. Of all Medicare...
White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition - Acta Neuropathologica Communications
Multi-compartment modelling of white matter microstructure using Neurite Orientation Dispersion and Density Imaging (NODDI) can provide information on white matter health through neurite density index and free water measures. We hypothesized that cerebrovascular disease, Alzheimer’s disease, and TDP-43 proteinopathy would be associated with distinct NODDI readouts of white matter damage which would be informative for identifying the substrate fo…
According to a study by UVA Health of the University of Virginia, in the United States, an antiviral medicine used in patients for HIV can serve as a preventive therapy for Alzheimer's disease. Researchers found that taking this type of antiviral could help to reduce the likelihood of developing the disease. Jayakrishna Ambata, one of the authors of the study, revealed that there was a 10% reduction in the risk of developing the disease by peopl…
Coverage Details
Bias Distribution
- 75% of the sources are Center
To view factuality data please Upgrade to Premium
